

AMENDMENT

OFFERED BY MR. BOUSTANY OF LOUISIANA

In division B, insert after section 1401 (relating to Comparative effectiveness research) the following new section (and update the table of contents accordingly):

1 **SECTION 1402. PROCESS FOR CERTAIN NATIONAL COV-**
2 **ERAGE DETERMINATIONS.**

3 (a) **REQUIREMENTS FOR THE ISSUANCE OF CERTAIN**
4 **MEDICARE NATIONAL COVERAGE DETERMINATIONS.—**

5 Unless all of the conditions under subsection (b) are met,
6 the Administrator may not issue a final national coverage
7 determination (referred to in this Act as a NCD)—

8 (1) if the NCD restricts local or national cov-
9 erage for an item or service that, before the date of
10 the issuance of such NCD, was routinely covered
11 under the Medicare program under title XVIII of
12 the Social Security Act;

13 (2) if the NCD would result in significant cost
14 savings for the Medicare program;

15 (3) if there is controversy in the available peer-
16 reviewed medical and scientific literature about the
17 evidence supporting the NCD;

1 (4) if the NCD restricts local or national cov-
2 erage for an item or service that—

3 (A) is supported by current clinical prac-
4 tice guidelines—

5 (i) included in the National Guideline
6 Clearinghouse maintained by the Agency
7 for Healthcare Research and Quality; or

8 (ii) maintained by a State medical so-
9 ciety; or

10 (B) is endorsed by the National Quality
11 Forum or by another national organization that
12 evaluates voluntary consensus-based provides
13 quality measures and is designated by the Sec-
14 retary for purposes of making an endorsement
15 under this subparagraph; or

16 (5) if the Administrator determines that—

17 (A) significant differences in opinion exist
18 among experts concerning—

19 (i) what evidence should be reviewed
20 in developing the NCD; or

21 (ii) how data should be interpreted for
22 purposes of developing the NCD; and

23 (B) an independent analysis of the evi-
24 dence and data analysis would be valuable in
25 developing the final NCD.

1 (b) REQUIRED CONDITIONS.—The conditions under
2 this subsection are as follows:

3 (1) REQUEST FOR REVIEW.—Before the start
4 of the public comment period for a proposed NCD
5 that contains all the restrictions on the coverage of
6 products and services included in the final NCD, the
7 Administrator makes a formal request to MEDCAC
8 for a review of the scientific and clinical evidence
9 supporting and opposing the NCD.

10 (2) MEDCAC REVIEW SUBCOMMITTEE.—

11 (A) IN GENERAL.—MEDCAC convenes a
12 subcommittee to—

13 (i) review the evidence supporting the
14 proposed NCD (including clinical practice
15 guidelines published by medical specialty
16 societies), taking into account—

17 (I) the evidence related to sub-
18 populations of beneficiaries (including
19 men, women, racial and ethnic minori-
20 ties, the elderly, individuals with dis-
21 abilities, and individuals with genetic
22 variations); and

23 (II) the extent to which patient
24 preference is a factor in the use of the

1 item or service that is the subject of
2 the NCD;

3 (ii) conduct an evaluation of the clin-
4 ical and scientific evidence relating to the
5 clinical benefits and risks of a technology
6 affected by such NCD; and

7 (iii) determine if the NCD will limit
8 the access of Medicare beneficiaries to
9 medically necessary care.

10 (B) MEMBERSHIP.—The subcommittee
11 under subparagraph (A) shall have 15 mem-
12 bers, each of whom—

13 (i) shall be a clinical expert in the
14 medical specialty or specialties that are
15 most relevant to the topic of the NCD; and

16 (ii) to the extent feasible, shall have
17 expertise in the development of clinical
18 practice guidelines.

19 (C) OUTSIDE EXPERTS ALLOWED.—
20 MEDCAC may include individuals who are not
21 members of MEDCAC in the membership of
22 the subcommittee convened under subparagraph
23 (A).

24 (3) SUBCOMMITTEE COMMENT.—

1 (A) IN GENERAL.—Not later than the last
2 day of the period under paragraph (1), the sub-
3 committee convened under paragraph (3)(A)
4 shall submit to the Administrator a public com-
5 ment on the NCD that contains an evaluation
6 of whether—

7 (i) the NCD is appropriate based on
8 the subcommittee's activities under para-
9 graph (2)(A);

10 (ii) the NCD is consistent with clinical
11 guidelines;

12 (iii) the NCD would adversely impact
13 access the access of subpopulations to
14 items or services which may benefit such
15 subpopulations; or

16 (iv) the NCD would adversely impact
17 access to treatment options that are pri-
18 marily selected by patients, with their phy-
19 sicians, based on patient preference and
20 quality of life criteria.

21 (B) NCDS THAT PREVENT ACCESS TO
22 CARE.—If MEDCAC determines that the pro-
23 posed NCD could prevent Medicare patients
24 from receiving medically necessary care, the
25 MEDCAC panel shall include in such public

1 comment a recommendation that the proposed
2 NCD not be issued as a final NCD.

3 (c) RESTRICTION ON ADDITIONAL LIMITATION ON
4 COVERAGE.—The Administrator may not issue a final
5 NCD that contains any restrictions on the coverage of
6 products and services that were not included in the pro-
7 posed NCD reviewed under subsection (b).

8 (d) CONSTRUCTION.—Nothing in this Act shall be
9 construed as preventing a Medicare beneficiary from using
10 private funds to purchase supplemental health insurance
11 coverage or to directly purchase medically necessary care.

12 (e) DEFINITIONS.—For purposes of this section:

13 (1) ADMINISTRATOR.—The term “Adminis-
14 trator” means the Administrator of CMS.

15 (2) CMS.—The term “CMS” means the Cen-
16 ters for Medicare & Medicaid Services.

17 (3) MEDCAC.—The term “MEDCAC” means
18 the Medicare Evidence Development & Coverage Ad-
19 visory Committee established by the Secretary of
20 Health and Human Services pursuant to section 222
21 of the Public Health Service Act.

22 (4) MEDICALLY NECESSARY SERVICES.—The
23 term “medically necessary care” means health care
24 services or products that a prudent physician would
25 provide to a patient for the purpose of preventing,

1 diagnosing, treating or rehabilitating an illness, in-
2 jury, disease or its associated symptoms, impair-
3 ments or functional limitations in a manner that
4 is—

5 (A) in accordance with generally accepted
6 standards of medical practice;

7 (B) clinically appropriate in terms of type,
8 frequency, extent, site and duration; and

9 (C) not primarily for the convenience of
10 the patient, physician, or other health care pro-
11 vider.

12 (5) MEDPAC.—The term “MedPAC” means
13 the Medicare Payment Advisory Commission estab-
14 lished under Section 1805 of the Social Security Act.

15 (6) NATIONAL COVERAGE DETERMINATION.—
16 The term “national coverage determination” has the
17 meaning given such term in section 1869(f)(1)(B) of
18 the Social Security Act.

